Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 95,505 shares, a decline of 99.1% from the August 15th total of 10,331,073 shares. Based on an average daily volume of 71,248 shares, the short-interest ratio is currently 1.3 days. Currently, 8.8% of the company’s stock are sold short.
Liminatus Pharma Price Performance
Shares of LIMN traded up $0.02 during midday trading on Friday, hitting $3.65. The stock had a trading volume of 8,837 shares, compared to its average volume of 381,351. The firm has a market cap of $4.89 million, a price-to-earnings ratio of -0.16 and a beta of 5.30. The company has a 50 day simple moving average of $5.35 and a two-hundred day simple moving average of $7.89. Liminatus Pharma has a twelve month low of $3.42 and a twelve month high of $141.50.
Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($1.50) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on LIMN
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
See Also
- Five stocks we like better than Liminatus Pharma
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
- Oracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in Earnings
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
